Literature DB >> 24507757

Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study.

Hiroaki Kajiyama1, Mika Mizuno2, Kiyosumi Shibata2, Eiko Yamamoto2, Michiyasu Kawai3, Tetsuro Nagasaka4, Fumitaka Kikkawa2.   

Abstract

OBJECTIVES: We reviewed the clinical outcomes of patients with early-stage epithelial ovarian cancer (EOC) who had undergone fertility-sparing surgery (FSS) to assess recurrence-free survival (RFS). STUDY
DESIGN: After central pathological review and scanning of the medical records of multiple institutions, a total of 94 patients with stage I EOC (IA: 43 and IC: 51) treated with FSS were analyzed. IC substages were defined as follows: intraoperative spillage (IC1), preoperative capsule rupture or surface invasion (IC2), and positive cytology results (IC3).
RESULTS: The median age was 30.5 (13-40) years. The median follow-up time was 66.6 months. Fourteen patients (14.9%) showed carcinoma recurrence. Eleven (11.7%) patients died of the disease. The total 5-year RFS rate including all women who received FSS was 84.3%. There was no significant difference in RFS between patients with IC1 and those with stage IA (P=0.9411). In contrast, the RFS rate of patients with IC2/3 was significantly poorer than in patients with stage IA (IA vs. IC2/3: P=0.0487, IC1 vs. IC2/3: P=0.0471). In further analyses according to each histological type and grade, the RFS rate of subjects with the mucinous type was the same as that of those with a clear-cell histology (P=0.3350). There was a significant difference in RFS of patients with grade 1 (G1) and G2-3 (P=0.0004). To eliminate selection bias from a number of clinicopathologic factors as thoroughly as possible, the age, FIGO stage, histological type, grade, and postoperative adjuvant chemotherapy were entered into multivariate RFS analyses. Cox multivariable analysis showed that the substage group and grade were independent prognostic factors for RFS.
CONCLUSIONS: Confined to young women with intraoperative rupture, FSS may be proposed, if without tumor-associated dense adhesion. However, those with preoperative rupture, surface invasion, and positive cytology showed a greater risk of recurrence, suggesting that they are not recommended candidates. Although patients with G2-3 tumors showed a poorer prognosis than those with G1, the number of these subjects was so small that the current results should be reconfirmed in the next study.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Capsule rupture; Epithelial ovarian cancer; Fertility-sparing surgery (FSS); Prognostic factor; Recurrence-free survival

Mesh:

Year:  2014        PMID: 24507757     DOI: 10.1016/j.ejogrb.2014.01.014

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  12 in total

1.  Oncological and Reproductive Outcomes After Fertility-Sparing Surgery for Stage I Mucinous Ovarian Carcinoma.

Authors:  Wei Lin; Dongyan Cao; Xiaohua Shi; Yan You; Jiaxin Yang; Keng Shen
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma.

Authors:  Hai Ming Li; Jin Wei Qiang; Gan Lin Xia; Shu Hui Zhao; Feng Hua Ma; Song Qi Cai; Feng Feng; Ai Yan Fu
Journal:  J Ovarian Res       Date:  2015-04-30       Impact factor: 4.234

3.  Fertility sparing surgery in patients with early stage epithelial ovarian cancer: implication of survival analysis and lymphadenectomy.

Authors:  Hiroaki Kajiyama
Journal:  J Gynecol Oncol       Date:  2014-10       Impact factor: 4.401

4.  Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer.

Authors:  Robert Fruscio; Lorenzo Ceppi; Silvia Corso; Francesca Galli; Tiziana Dell'Anna; Federica Dell'Orto; Daniela Giuliani; Annalisa Garbi; Stefania Chiari; Costantino Mangioni; Rodolfo Milani; Irene Floriani; Nicoletta Colombo; Cristina Maria Bonazzi
Journal:  Br J Cancer       Date:  2016-08-18       Impact factor: 7.640

5.  Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma?

Authors:  Dimitrios Nasioudis; Eloise Chapman-Davis; Melissa K Frey; Steven S Witkin; Kevin Holcomb
Journal:  J Gynecol Oncol       Date:  2017-07-03       Impact factor: 4.401

6.  Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age.

Authors:  Xuan Jiang; Jiaxin Yang; Mei Yu; Weimin Xie; Dongyan Cao; Ming Wu; Lingya Pan; Huifang Huang; Yan You; Keng Shen
Journal:  World J Surg Oncol       Date:  2017-08-15       Impact factor: 2.754

7.  A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women.

Authors:  Gry Johansen; Pernilla Dahm-Kähler; Christian Staf; Angelique Flöter Rådestad; Kenny A Rodriguez-Wallberg
Journal:  BMC Cancer       Date:  2020-10-19       Impact factor: 4.430

8.  Feasibility and safety of fertility-sparing surgery in epithelial ovarian cancer with dense adhesion: a long-term result from a single institution.

Authors:  Min Hyun Baek; Jeong Yeol Park; Dae Yeon Kim; Dae Shik Suh; Jong Hyeok Kim; Yong Man Kim; Young Tak Kim
Journal:  J Gynecol Oncol       Date:  2020-11       Impact factor: 4.401

9.  The prognostic impact of pulmonary metastasectomy in recurrent gynecologic cancers: a retrospective single-institution study.

Authors:  Manabu Adachi; Mika Mizuno; Hiroko Mitsui; Hiroaki Kajiyama; Shiro Suzuki; Ryuichiro Sekiya; Fumi Utsumi; Kiyosumi Shibata; Tetsuo Taniguchi; Koji Kawaguchi; Kohei Yokoi; Fumitaka Kikkawa
Journal:  Nagoya J Med Sci       Date:  2015-08       Impact factor: 1.131

10.  Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.

Authors:  Jun Hu; Xiaobing Jiao; Lirong Zhu; Hongyan Guo; Yumei Wu
Journal:  BMC Cancer       Date:  2020-09-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.